QQ客服 官方微博 反馈留言

浏览/检索结果: 共9条，第1-9条 帮助 限定条件 发表日期：2015    专题：吉林大学白求恩第一医院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 15 作者:  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun;  Syrigos, Konstantinos N. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 A fatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial 会议论文 作者:  Gadgeel, Shirish;  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05 Lung cancer / Oncology   Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 15 作者:  Gadgeel, Shirish M.;  Dols, Manuel Cobo;  Felip, Enriqueta;  Soria, Jean-Charles;  Lee, Ki Hyeong 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05 LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy 会议论文 作者:  Hirsh, Vera;  Gadgeel, Shirish;  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05 Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes 期刊论文 EUROPEAN JOURNAL OF CANCER, 2015, 卷号: 51 作者:  Goss, G. D.;  Felip, E.;  Cobo, M.;  Lu, S.;  Syrigos, K. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05 Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 15 作者:  Gadgeel, Shirish M.;  Dols, Manuel Cobo;  Felip, Enriqueta;  Soria, Jean-Charles;  Lee, Ki Hyeong 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05 Test on existence of histology subtype-specific prognostic signatures among early stage lung adenocarcinoma and squamous cell carcinoma patients using a Cox-model based filter 期刊论文 BIOLOGY DIRECT, 2015, 卷号: 10 作者:  Tian, Suyan;  Wang, Chi;  An, Ming-Wen 收藏  |  浏览/下载：13/0  |  提交时间：2019/12/05 Non-small cell lung cancer (NSCLC)  Adenocarcinoma (AC)  Squamous cell carcinoma (SCC)  Cox model  Prognosis  Histology-subtype specific  Gene expression barcode  Feature selection algorithm   Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes 期刊论文 ANNALS OF ONCOLOGY, 2015, 卷号: 26 作者:  Park, K.;  Li, W.;  Zhou, C.;  Felip, E.;  Cobo, M. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes 会议论文 作者:  Park, K.;  Li, W.;  Zhou, C.;  Felip, E.;  Cobo, M. 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05